(Reuters) -Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized ...

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) has announced that it has signed an access agreement with Pharmaceutical Company Gilead Sciences to procure lenacapavir, a ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Gilead Sciences, Inc. (GILD) on Wednesday announced a strategic partnership agreement with the Global Fund to combat AIDS, ...

Only 17,000 Ugandans to benefit from $1.1m Global Fund support as officials warn of high demand for long-acting prevention ...

Gilead has partnered with Global Fund to supply lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP).

Severe cuts to international aid are disrupting lifesaving HIV services in vulnerable countries, with UNAIDS warning of millions of preventable infections and deaths if support isn’t restored.

Gilead Sciences (NasdaqGS:GILD) recently announced a partnership with the Global Fund to supply lenacapavir for HIV ...

The National Agency for the Control of AIDS (NACA) is set to host a high-level meeting to deliberate on sustainable ...

The Minister’s address was particularly notable for the announcement of a planned rollout of lenacapavir, a biannual ...

Strategies that address population-specific concerns about medical mistrust and employ operational tactics, including staff ...

Nigeria must take bold steps to ensure that HIV prevention, treatment, and support remain accessible and resilient, ...